# Phosphorylations of serines 21/9 in glycogen synthase kinase 3α/β are dispensable for V600EBRAF-driven premalignant tumour development in the mouse intestine

## TL;DR

This study shows that phosphorylation of GSK3αβ at serines 21/9 is not essential for tumor development in mice with a specific BRAF mutation in the intestine.

## Contribution

The study demonstrates that GSK3αβ phosphorylation at S21/S9 is dispensable for V600EBRAF-driven tumor development in the mouse intestine.

## Key findings

- Phosphorylation of GSK3αβ at S21/S9 has a marginal effect on crypt proliferation in the short term.
- Long-term tumorigenesis and survival are unaffected by GSK3αβ S21/S9 phosphorylation mutations.
- Only three genes are significantly affected by the GSK3αβ knock-in mutations.

## Abstract

Valine to glutamate substitution at residue 600 of the BRAF oncogene (V600EBRAF mutation) is prevalent in human colorectal cancers with a serrated histopathology and is thought to be a founder mutation. Using a conditional knock-in mouse model we have previously demonstrated that V600EBraf drives crypt hyperplasia in the short term as well as shortened survival linked to increased tumour burden in the long-term. These phenotypes are associated with induction of gene signatures for E2F targets, MYC signalling, G2/M transition, canonical Wnt signalling, and cholesterol biosynthesis. Although these gene signatures are reverted by MEK inhibition, there remains a lack of understanding of the signalling pathways involved, particularly the mechanism of crosstalk between the MAPK and Wnt pathways. Here, we have examined a role for phosphorylation of GSK3αβ isoforms at residues S21/S9. By introducing homozygous knock-in mutations for Gsk3αβS9A/S21A onto the V600EBraf background, we unexpectedly show a marginal effect of these mutations on further increasing crypt proliferation. However, this impact is lost in the long-term as there are no significant differences in mouse survival, tumour burden or tumour grade. Consistently, the Gsk3αβ knock-in mutations do not change the transcriptional programme induced by V600EBraf, except for 3 genes (Ephx4, Eif2b3 Ppp1r13l) whose expression is significantly altered, potentially contributing to the short-term increase in crypt hyperplasia. Overall, our data show that therapeutic strategies targeting GSK3αβ phosphorylation at serines 21/9 are not worthwhile options for V600EBRAF colorectal cancers.